Circulating Insulin-Like Growth Factors and IGF-Binding Proteins in PSA-Detected Prostate Cancer: The Large Case–Control Study ProtecT
- 15 January 2012
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 72 (2) , 503-515
Abstract
Circulating insulin-like growth factor-I (IGF-I) has been studied extensively in prostate cancer, but there is still little information about IGFs and IGF-binding proteins (IGFBP) in cancers detected by the prostate-specific antigen (PSA) test. Here, we report the findings of a U.K.-based case–control study to investigate circulating IGFs and IGFBPs in PSA-detected prostate cancer with regard to their potential associations with different cancer stages or grades. PSA testing was offered to 110,000 men aged 50 to 69 years from 2002 to 2009. Participants with an elevated level of PSA (≥3.0 ng/mL) underwent prostate biopsy and measurements of blood serum IGF-I, IGF-II, IGFBP-2, and IGFBP-3 obtained at recruitment. We found that serum levels of IGF-II (OR per SD increase: 1.16; 95% CI: 1.08–1.24; Ptrend < 0.001), IGFBP-2 (1.18; 1.06–1.31; Ptrend < 0.01) and IGFBP-3 (1.27; 1.19–1.36; Ptrend < 0.001), but not IGF-I (0.99; 0.93–1.04; Ptrend = 0.62), were associated with PSA-detected prostate cancer. After controlling for IGFBP-3, IGF-II was no longer associated (0.99; 0.91–1.08; Ptrend = 0.62) and IGF-I was inversely associated (0.85; 0.79–0.91; Ptrend < 0.001) with prostate cancer. In addition, no strong associations existed with cancer stage or grade. Overall, these findings suggest potentially important roles for circulating IGF-II, IGFBP-2, and IGFBP-3 in PSA-detected prostate cancer, in support of recent in vitro evidence. Although our findings for IGF-I agree with previous results from PSA screening trials, they contrast with positive associations in routinely detected disease, suggesting that reducing levels of circulating IGF-I might not prevent the initiation of prostate cancer but might, nonetheless, prevent its progression. Cancer Res; 72(2); 503–15. ©2011 AACR.Keywords
All Related Versions
This publication has 59 references indexed in Scilit:
- Plasma insulin‐like growth factor 1 is positively associated with low‐grade prostate cancer in the Health Professionals Follow‐up Study 1993–2004International Journal of Cancer, 2010
- Latest results from the UK trials evaluating prostate cancer screening and treatment: The CAP and ProtecT studiesEuropean Journal of Cancer, 2010
- Plasma Levels of Acid-Labile Subunit, Free Insulin-Like Growth Factor-I, and Prostate Cancer Risk: A Prospective StudyCancer Epidemiology, Biomarkers & Prevention, 2010
- Illustrating bias due to conditioning on a colliderInternational Journal of Epidemiology, 2009
- Identification of seven new prostate cancer susceptibility loci through a genome-wide association studyNature Genetics, 2009
- Circulating insulin‐like growth factor peptides and prostate cancer risk: A systematic review and meta‐analysisInternational Journal of Cancer, 2009
- Lead Time and Overdiagnosis in Prostate-Specific Antigen Screening: Importance of Methods and ContextJNCI: Journal of the National Cancer Institute, 2009
- Risk factors for prostate cancer incidence and progression in the health professionals follow‐up studyInternational Journal of Cancer, 2007
- Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancerProceedings of the National Academy of Sciences, 2007
- Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysisThe Lancet, 2004